IFNA16

Across TCGA pan-cancer cohorts, IFNA16 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated IFNA16 data layer compared with 7 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher IFNA16 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IFNA16 expression acts as an unfavorable survival marker.

BLCA, HNSC, and PRAD are the cancer types where IFNA16 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	III,IV	0.051	0.684	<.001	24	view →
HNSC	DFS	Median	II,III,IV	0.194	0.661	.031	9	view →
PRAD	DFS	Median	All	0.107	0.886	<.001	6	view →
LUAD	OS	Median	All	0.243	0.700	.001	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

IFNA16–BLCA (OS)

Open the BLCA breakdown →